Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HTR1E | P28566 | 1/20 | 0.50 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3224174 | 0.93 | NPSR1 (0.55) | NPSR1MAPTHTR1ES1PR3TDP1 | |
| SCHEMBL3900070 | 0.93 | AKR1C1 (0.59) | NPSR1MAPTHTR1ES1PR3TDP1 | |
| SCHEMBL3904809 | 0.89 | L3MBTL1 (0.64) | NPSR1MAPTHTR1ES1PR3TDP1 | |
| SCHEMBL18040073 | 0.84 | TSHR (0.52) | NPSR1MAPTHTR1ES1PR3TDP1 | |
| SCHEMBL5366626 | 0.84 | ALDH1A1 (0.52) | NPSR1MAPTHTR1ES1PR3TDP1 | |
| SCHEMBL6607473 | 0.84 | NPSR1 (0.52) | NPSR1MAPTHTR1ES1PR3TDP1 | |
| SCHEMBL3909752 | 0.83 | ALDH1A1 (0.55) | NPSR1MAPTHTR1ES1PR3MEN1 | |
| SCHEMBL10349986 | 0.83 | NPSR1 (0.46) | NPSR1MAPTHTR1ES1PR3TDP1 | |
| SCHEMBL10549794 | 0.83 | NPSR1 (0.46) | NPSR1MAPTHTR1ES1PR3TDP1 | |
| SCHEMBL10548355 | 0.82 | CES1 (0.44) | NPSR1MAPTHTR1ES1PR3TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1161962-A | Sulphonic-acid-amide derivative | KONO PHARMACEUTICAL IND K K (JP) | 1997-10-15 | — | — | CN | claimed |
| US-11077115-B2 | Rorgamma modulators and uses thereof | GENFIT (FR) | 2021-08-03 | — | — | US | disclosed |
| US-11052092-B2 | N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases | GENFIT (FR) | 2021-07-06 | — | — | US | disclosed |
| US-9187453-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-17 | — | — | US | disclosed |
| US-20150094296-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-02 | — | — | US | disclosed |
| EP-2832734-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-02-04 | — | — | EP | disclosed |
| WO-2011061760-A1 | NOVEL ANTITHROMBOTIC AGENTS | CADILA HEALTHCARE LIMITED (IN) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011061760-A1 | NOVEL ANTITHROMBOTIC AGENTS | CADILA HEALTHCARE LIMITED (IN) | 2011-05-26 | — | — | WO | disclosed |
| US-7166616-B2 | Substituted alkanoic acids | AVENTIS PHARMA LIMITED (GB) | 2007-01-23 | — | — | US | disclosed |
| WO-2005034837-A2 | 7H-IMIDAZO [1,2-α] PYRAZIN-8-ONE COMPOUNDS AS ION CHANNEL MODULATORS | CARDIOME PHARMA CORPORATION (US) | 2005-04-21 | — | — | WO | disclosed |
| US-20040006056-A1 | For therapy of disease states capable of being modulated by the inhibition of cell adhesion; therapy of asthma | AVENTIS PHARMA LIMITED (GB) | 2004-01-08 | — | — | US | disclosed |
| EP-1330432-A2 | SUBSTITUTED ALKANOIC ACIDS | Aventis Pharma Limited (GB) | 2003-07-30 | — | — | EP | disclosed |
| WO-2002036553-A2 | SUBSTITUTED ALKANOIC ACIDS | AVENTIS PHARMA LIMITED (GB) | 2002-05-10 | — | — | WO | disclosed |
| CN-1161962-A | Sulphonic-acid-amide derivative | KONO PHARMACEUTICAL IND K K (JP) | 1997-10-15 | — | — | CN | disclosed |
| US-4859232-A | Substituted-aryl cyclopropanecarbonitriles and derivatives thereof as herbicide antidotes | MONSANTO COMPANY (US) | 1989-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11052092-B2 | N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases | RORA, RORC, RORB | NPSR1 2259/4885MAPT 3199/4885HTR1E 3694/4885 |
| US-20150094296-A1 | HETEROCYCLIC COMPOUND | TYK2, SSB, UACA | NPSR1 2801/4885MAPT 277/4885HTR1E 3593/4885 |
| US-20040006056-A1 | For therapy of disease states capable of being modulated by the inhibition of cell adhesion; therapy of asthma | VCAM1, LTB4R, ITGA1 | NPSR1 175/4885MAPT 4800/4885HTR1E 261/4885 |
| US-11077115-B2 | Rorgamma modulators and uses thereof | RORB, RORC, RORA | NPSR1 1173/4885MAPT 4111/4885HTR1E 4409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.